Spondyloarthritis & psoriatic arthritis
Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years
Authors' conclusion
Patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at week 104 than patients with radiographic progression.
Study context
- Population
- Patients with active PsA enrolled in FUTURE 5, pooled by secukinumab treatment received at week 104 (300 mg with LD, 150 mg with LD, 150 mg without LD)
- Participants
- 541 patients
- Comparison
- Radiographic non-progressors vs radiographic progressors through week 104 of secukinumab
- Non-progressorsn = 457
- Progressorsn = 84reference
- Primary endpoint
- Achievement of MDA, VLDA and DAPSA LDA or remission by radiographic progression status
- Follow-up
- Week 104
Methodological detailspost hoc analysis, phase 3, logistic regression
- Post hoc analysis
- Phase 3
- Logistic regression
Primary result
As reported in the abstract
MDA, VLDA, DAPSA LDA and remission
Further findings
Factors associated with radiographic progression at week 104 (logistic regression)
- Progression associated with older age and higher baseline high-sensitivity CRP
- Non-progression associated with secukinumab 300 mg (vs 150 mg without LD), no prior TNFi exposure and lower BMI
Original publication
Relationship of radiographic progression status to low disease activity in patients with PsA receiving secukinumab treatment for 2 years. Rheumatology (Oxford). Published 18 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →